Chinese gene synthesis firm Tsingke Biotechnology has bagged 400 million yuan ($57.2 million) in a Series B round led by Fortune Capital as well as Henan CICC Huirong Fund Management, a fund jointly set up by Henan Investment Group and CICC Capital.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
